Vaccine Antigens against Acinetobacter Baumannii

Invention Description
Antimicrobial resistance has evolved to become a worldwide health threat. According to the RAND EUROPE reports, drug-resistant superbugs will kill more people than cancer and cost up to $100 trillion by 2050. Bacteria that cause nosocomial infection including Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae are classified by WHO as the priority 1 pathogens which new antibiotics are most urgently needed. Alternatively, vaccines that prevent infections and therefore reduce the use of antibiotics can help limit the spread of antibiotic resistance. According to GlobalData, the global market of healthcare-associated infections caused by Gram-negative bacteria was worth ~ US$1.3 billion in 2016 that is projected to grow ~10.6% annually to excess $3.6 billion in sales by 2026.

Safety pharmacology and general toxicology
1. No apparent side effects were observed in mice after immunization.
2. No cytotoxicity was observed when treating human cells A549 with 100 µg/mL of the vaccine antigens

Competitive Advantages
1. Conserved antigens of A. baumannii
2. Eliciting serum bactericidal activity
3. Inducing a long-term immunity
4. No obvious side effects

Intellectual Property
Patent: Taiwan, Japan, and USA
Pending: Brazil, Chain, and EP

Key Publication
Manuscripts in preparation

Business Opportunity
License and/or Collaboration and Sponsored Research

※ If you are interested in our technologies, please contact us here.

※欲下載完整檔案請 登入/會員註冊